Literature DB >> 505679

Composition of renal stones and their frequency in a stone clinic: relationship to parameters of mineral metabolism in serum and urine.

D Scholz, P O Schwille, D Ulbrich, W M Bausch, A Sigel.   

Abstract

Stone analyses (kidney, upper urinary tract) of the department of Urology, University of Erlangen, from a four-year-period (1974-1977) have been recorded with emphasis to stone composition, sex and age of the pertinent stone forming patients. During this time period there were no substantial changes as regards the per cent frequency of the various stone types. The most frequent type was calcium oxalate (CaOx), followed by uric acid, calcium phosphate (CaP), struvite and cystine. Stone analyses were mostly requested for patients between 46 and 55 years of age. Stone incidence in our clinic is calculated to be 1.22 times higher in males than females, especially beyond 36 years of age. The frequency peaks are: pure (= 100 per cent) CaOx 36-45 years; CaOx with additional mineral phases (mostly CaP) 46-55 years; uric acid 56-65 years; CaP 26-35 years. From those patients who underwent further investigations in searching for metabolic abnormalities serum concentrations, urine mineral clearances in fasting urine samples, and activity products of stone forming mineral phases in sequentially collected specimens from 24 h and 2 h fasting urine had been measured and compared with values from healthy control subjects. In urolithiasis (idiopathic) there is a normal parathyroid hormone blood level, a generally lower serum inorganic phosphate and magnesium concentration. In pure (= 100 per cent) CaOx and uric acid lithiasis serum uric acid and creatinine are higher than in controls, urine pH and calcium clearance in some groups are different too. Clearances of magnesium, uric acid, phosphate, sodium are within normal limits in urolithiasis. When expressing the propensity to form stones in terms of activity products, then only uric acid lithiasis deviates substantially from normal. All other stone types differ only slightly or not at all from each other and controls respectively. It is concluded that 1) in our geographic region the various stone types prevail in different age periods; 2) there are distinct alterations of parameters of mineral metabolism in urolithiasis; 3) measuring urine clearances may lead to assume falsely normal mean urine excretion of stone forming constituents.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 505679     DOI: 10.1007/bf00257201

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  18 in total

1.  An observation on the composition and recurrence of urinary calculi.

Authors:  E Takasaki
Journal:  Urol Int       Date:  1975       Impact factor: 2.089

2.  [Evaluation of renal cyclic adenosine monophosphate, serum parathyroid hormone and phosphate reabsorption in recurrent calcium urolithiasis, healthy controls and hyperparathyroidism (author's transl)].

Authors:  P O Schwille; C Bornhof; R Thun; D Scholz; R Bötticher; W Schellerer; A Sigel
Journal:  Klin Wochenschr       Date:  1978-06-15

3.  Fasting uric acid and phosphate in urine and plasma of renal calcium-stone formers.

Authors:  P Schwille; N Samberger; B Wach
Journal:  Nephron       Date:  1976       Impact factor: 2.847

Review 4.  Calcium-containing renal stones.

Authors:  L H Smith
Journal:  Kidney Int       Date:  1978-05       Impact factor: 10.612

5.  Nephrolithiasis.

Authors:  H E Williams
Journal:  N Engl J Med       Date:  1974-01-03       Impact factor: 91.245

6.  [Crystal-optical determination of urinary concrements].

Authors:  G Sorger; W M Bausch
Journal:  Urologe       Date:  1971-07       Impact factor: 0.639

7.  [Urinary oxalate in recurrent calcium urolithiasis with and without hyperfunctioning parathyroid glands and in healthy controls. influence of age and season (author's transl)].

Authors:  P O Schwille; M Paulus; D Scholz; A Sigel; E Wilhelm
Journal:  Urologe A       Date:  1979-07       Impact factor: 0.639

8.  Calculus disease of the urinary tract at a district hospital.

Authors:  P J Jeffery
Journal:  Postgrad Med J       Date:  1976-11       Impact factor: 2.401

9.  Dietary phosphate deprivation in women and men: effects on mineral and acid balances, parathyroid hormone and the metabolism of 25-OH-vitamin D.

Authors:  J H Dominguez; R W Gray; J Lemann
Journal:  J Clin Endocrinol Metab       Date:  1976-11       Impact factor: 5.958

10.  The relation between the concentration of calcium salts in the urine and renal stone composition in patients with calcium-containing renal stones.

Authors:  R W Marshall; M Cochran; W G Robertson; A Hodgkinson; B E Nordin
Journal:  Clin Sci       Date:  1972-09       Impact factor: 6.124

View more
  6 in total

1.  Fasting gastrinemia and elevated supersaturation with hydroxyapatite of fasting urine--observations in renal calcium stone patients and controls.

Authors:  P O Schwille; G Rümenapf; R Köhler; J H Weippert
Journal:  Urol Res       Date:  1987

2.  Crystalluria in idiopathic recurrent calcium urolithiasis. Dependence on stone composition.

Authors:  U Herrmann; P O Schwille
Journal:  Urol Res       Date:  1992

3.  Analysis of spontaneously passed urinary tract stones.

Authors:  Daniel Muñoz-Velez; Fernando Garcia-Montes; Antonia Costa-Bauza; Felix Grases
Journal:  Urol Res       Date:  2009-12-01

4.  Clinical and biochemical profile of patients with "pure" uric acid nephrolithiasis compared with "pure" calcium oxalate stone formers.

Authors:  Armando Luis Negri; Rodolfo Spivacow; Elisa Del Valle; Irene Pinduli; Alicia Marino; Erich Fradinger; Jose Ruben Zanchetta
Journal:  Urol Res       Date:  2007-09-06

Review 5.  A survey of calcium urolithiasis in normocalcemic hypercalciuria: possible role of nutrients and diet-mediated factors.

Authors:  P O Schwille
Journal:  Urol Res       Date:  1979-09

6.  Fourier transform infrared spectroscopy for analysis of kidney stones.

Authors:  Aysha Habib Khan; Sheharbano Imran; Jamsheer Talati; Lena Jafri
Journal:  Investig Clin Urol       Date:  2018-01-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.